申请人:——
公开号:US20020049212A1
公开(公告)日:2002-04-25
A compound of the formula:
1
or a pharmaceutically acceptable salt thereof, wherein R
1
is unsubstituted, mono-, di- or tri-substituted (C
3
-C
11
)cycloalkyl or (C
3
-C
11
)cycloalkenyl or the like, A is unsubstituted (C
1
-C
7
)alkyl or (C
2
-C
5
)alkenyl, hydroxy-(C
1
-C
4
)alkyl, (C
1
-C
4
)alkoxy-(C═O), or unsubstituted, mono-, di- or tri- substituted aryl, or aromatic-heterocyclic or the like, M is a covalent bond O, S, NH or the like, Y is 4- to 12-membered bicyclic-carbocyclic rings or 4- to 12-membered bicyclic-heterocyclic rings, or 5- to 17 membered spirocarbocyclic rings or 5- to 17-membered spiroheterocyclic rings or the like, Z
1
, Z
2
, Z
3
and Z
4
are hydrogen or the like, is disclosed. These compounds have ORL
1
-receptor agonist activity, and are thus useful as analgesics or the like in mammalian subjects.
一种化合物的公式:1或其药学上可接受的盐,其中R1为未取代、单取代、双取代或三取代的(C3-C11)环烷基或(C3-C11)环烯基等,A为未取代的(C1-C7)烷基或(C2-C5)烯基、羟基-(C1-C4)烷基、(C1-C4)氧基-(C═O),或未取代、单取代、双取代或三取代芳基、芳香杂环或类似物,M为共价键O、S、NH或类似物,Y为4-至12-成员双环碳环或4-至12-成员双环杂环,或5-至17-成员螺环碳环或5-至17-成员螺环杂环或类似物,Z1、Z2、Z3和Z4为氢或类似物。这些化合物具有ORL1受体激动剂活性,因此在哺乳动物主体中可用作镇痛剂或类似物。